Oxidative stress and Nrf2 expression in peripheral blood mononuclear cells derived from COPD patients: an observational longitudinal study.
COPD progression
Nrf2/ARE gene expression
Oxidative stress
PBMCs
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
30 Jan 2020
30 Jan 2020
Historique:
received:
21
08
2019
accepted:
14
01
2020
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
24
11
2020
Statut:
epublish
Résumé
A persistent low inflammatory-oxidative status and the inadequacy of the antioxidant nuclear factor-E2-related factor 2 (Nrf2) have been implicated in chronic obstructive pulmonary disease (COPD) progression. Therefore this study was aimed to assess the association between lung function decline and oxidative-inflammatory markers and Nrf2 signaling pathway expression in peripheral blood mononuclear cells (PBMCs) over time. 33 mild-moderate COPD outpatients (mean age 66.9 ± 6.9 years) were age-sex matched with 37 no-COPD subjects. A clinical evaluation, blood sampling tests and a spirometry were performed at baseline and after a mean follow-up of 49.7 ± 6.9 months. In COPD, compared to no-COPD, we found a faster lung function decline at follow-up. Although similar prevalence of smoking, hypertension, diabetes and dyslipidemia, systemic markers of inflammation (hs-CRP and white blood cells, WBCs) and oxidative stress (8-isoprostane) were significantly increased in COPD at follow-up, while the antioxidant glutathione (GSH) was significantly reduced. Moreover the expression of Nrf2 and of Nrf2-related genes heme oxygenase (HO)-1 and glutamate-cysteine ligase catalytic (GCLC) subunit in PBMCS were significantly down-regulated in COPD at follow-up, whereas no changes were observed in no-COPD. The percent variation (Δ) of FEV Although our results must be confirmed in larger trial they suggest that the down-regulation of Nrf2/ARE gene expression in PBMCs may be one of the determinants of FEV
Sections du résumé
BACKGROUND
BACKGROUND
A persistent low inflammatory-oxidative status and the inadequacy of the antioxidant nuclear factor-E2-related factor 2 (Nrf2) have been implicated in chronic obstructive pulmonary disease (COPD) progression. Therefore this study was aimed to assess the association between lung function decline and oxidative-inflammatory markers and Nrf2 signaling pathway expression in peripheral blood mononuclear cells (PBMCs) over time.
METHODS
METHODS
33 mild-moderate COPD outpatients (mean age 66.9 ± 6.9 years) were age-sex matched with 37 no-COPD subjects. A clinical evaluation, blood sampling tests and a spirometry were performed at baseline and after a mean follow-up of 49.7 ± 6.9 months.
RESULTS
RESULTS
In COPD, compared to no-COPD, we found a faster lung function decline at follow-up. Although similar prevalence of smoking, hypertension, diabetes and dyslipidemia, systemic markers of inflammation (hs-CRP and white blood cells, WBCs) and oxidative stress (8-isoprostane) were significantly increased in COPD at follow-up, while the antioxidant glutathione (GSH) was significantly reduced. Moreover the expression of Nrf2 and of Nrf2-related genes heme oxygenase (HO)-1 and glutamate-cysteine ligase catalytic (GCLC) subunit in PBMCS were significantly down-regulated in COPD at follow-up, whereas no changes were observed in no-COPD. The percent variation (Δ) of FEV
CONCLUSIONS
CONCLUSIONS
Although our results must be confirmed in larger trial they suggest that the down-regulation of Nrf2/ARE gene expression in PBMCs may be one of the determinants of FEV
Identifiants
pubmed: 32000766
doi: 10.1186/s12931-020-1292-7
pii: 10.1186/s12931-020-1292-7
pmc: PMC6993453
doi:
Substances chimiques
NF-E2-Related Factor 2
0
NFE2L2 protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Commentaires et corrections
Type : ErratumIn
Références
Int J Chron Obstruct Pulmon Dis. 2016 Jul 28;11:1733-43
pubmed: 27555763
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Respiration. 2011;81(6):499-510
pubmed: 21430361
Am J Respir Crit Care Med. 2009 Dec 15;180(12):1196-207
pubmed: 19797762
Chest. 2013 Jul;144(1):266-273
pubmed: 23880677
Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82
pubmed: 11804867
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Am J Respir Cell Mol Biol. 2008 Dec;39(6):673-82
pubmed: 18566336
Oxid Med Cell Longev. 2019 Jan 8;2019:7090534
pubmed: 30728889
Thorax. 2000 Jan;55(1):12-8
pubmed: 10607796
Expert Opin Ther Targets. 2010 Mar;14(3):329-46
pubmed: 20148719
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1991-7
pubmed: 17600225
J Clin Bioinforma. 2011 Apr 24;1(1):12
pubmed: 21884629
Free Radic Biol Med. 2009 Feb 1;46(3):376-86
pubmed: 19027064
Lancet. 2007 Jul 14;370(9582):109-110
pubmed: 17630021
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1063-1073
pubmed: 31213788
Biochem Biophys Res Commun. 2010 Dec 17;403(3-4):452-6
pubmed: 21094147
COPD. 2004 Apr;1(1):105-41; discussion 103-4
pubmed: 16997745
J Mol Med (Berl). 2011 Jun;89(6):577-93
pubmed: 21318260
J Immunol. 2005 Nov 15;175(10):6968-75
pubmed: 16272357
Thorax. 2006 Feb;61(2):115-21
pubmed: 16055612
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381-90
pubmed: 10673175
Ther Adv Respir Dis. 2008 Dec;2(6):351-74
pubmed: 19124382
Eur J Epidemiol. 2005;20(5):443-53
pubmed: 16080593
Toxicol Appl Pharmacol. 2010 Apr 1;244(1):43-56
pubmed: 19646463
PLoS One. 2009 Dec 09;4(12):e8225
pubmed: 20011043
Eur Respir J. 2005 Nov;26(5):835-45
pubmed: 16264044
J Clin Invest. 2004 Nov;114(9):1248-59
pubmed: 15520857
Genes Cells. 2005 Dec;10(12):1113-25
pubmed: 16324149
Epidemiol Rev. 2002;24(1):39-53
pubmed: 12119854
Am J Physiol Lung Cell Mol Physiol. 2014 Aug 1;307(3):L205-18
pubmed: 24879054
Int Arch Allergy Immunol. 2010;152(3):255-63
pubmed: 20150743
Lancet. 2006 Apr 15;367(9518):1216-9
pubmed: 16631861
Thorax. 1998 Jul;53(7):601-12
pubmed: 9797762
Thorax. 2008 Oct;63(10):916-24
pubmed: 18559366
Eur Respir J. 2006 Feb;27(2):397-412
pubmed: 16452599
Eur Respir J. 1993 Mar;6 Suppl 16:5-40
pubmed: 24576915
Am J Respir Crit Care Med. 2008 Sep 15;178(6):592-604
pubmed: 18556627
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12517-22
pubmed: 16894167
Int J Chron Obstruct Pulmon Dis. 2012;7:95-9
pubmed: 22371650